» Articles » PMID: 34702791

Autism-Like Behavioral Phenotypes in Mice Treated with Systemic N-Methyl-D-Aspartate

Overview
Specialty Pharmacology
Date 2021 Oct 27
PMID 34702791
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Autism spectrum disorder (ASD) having core characteristics of social interaction problems and repetitive behaviors and interests affects individuals at varying degrees and comorbidities, making it difficult to determine the precise etiology underlying the symptoms. Given its heterogeneity, ASD is difficult to treat and the development of therapeutics is slow due to the scarcity of animal models that are easy to produce and screen with. Based on the theory of excitation/inhibition imbalance in the brain with ASD which involves glutamatergic and/or GABAergic neurotransmission, a pharmacologic agent to modulate these receptors might be a good starting point for modeling. N-methyl-D-aspartic acid (NMDA) is an amino acid derivative acting as a specific agonist at the NMDA receptor and therefore imitates the action of the neurotransmitter glutamate on that receptor. In contrast to glutamate, NMDA selectively binds to and regulates the NMDA receptor, but not other glutamate receptors such as AMPA and kainite receptors. Given this role, we aimed to determine whether NMDA administration could result in autistic-like behavior in adolescent mice. Both male and female mice were treated with saline or NMDA (50 and 75 mg/kg) and were tested on various behavior experiments. Interestingly, acute NMDA-treated mice showed social deficits and repetitive behavior similar to ASD phenotypes. These results support the excitation/inhibition imbalance theory of ASD and that NMDA injection can be used as a pharmacologic model of ASD-like behaviors.

Citing Articles

Behavioral Deficits in Adolescent Mice after Sub-Chronic Administration of NMDA during Early Stage of Postnatal Development.

Adil K, Remonde C, Gonzales E, Boo K, Kwon K, Kim D Biomol Ther (Seoul). 2022; 30(4):320-327.

PMID: 35135902 PMC: 9252881. DOI: 10.4062/biomolther.2021.194.

References
1.
Jeon S, Gonzales E, Mabunga D, Valencia S, Kim D, Kim Y . Sex-specific Behavioral Features of Rodent Models of Autism Spectrum Disorder. Exp Neurobiol. 2018; 27(5):321-343. PMC: 6221834. DOI: 10.5607/en.2018.27.5.321. View

2.
Kim K, Gonzales E, Lazaro M, Choi C, Bahn G, Yoo H . Clinical and Neurobiological Relevance of Current Animal Models of Autism Spectrum Disorders. Biomol Ther (Seoul). 2016; 24(3):207-43. PMC: 4859786. DOI: 10.4062/biomolther.2016.061. View

3.
Saitow F, Takumi T, Suzuki H . Change in serotonergic modulation contributes to the synaptic imbalance of neuronal circuit at the prefrontal cortex in the 15q11-13 duplication mouse model of autism. Neuropharmacology. 2020; 165:107931. DOI: 10.1016/j.neuropharm.2019.107931. View

4.
Baranova J, Dragunas G, Botellho M, Ayub A, Bueno-Alves R, Alencar R . Autism Spectrum Disorder: Signaling Pathways and Prospective Therapeutic Targets. Cell Mol Neurobiol. 2020; 41(4):619-649. PMC: 11448616. DOI: 10.1007/s10571-020-00882-7. View

5.
Smalley S . Genetic influences in childhood-onset psychiatric disorders: autism and attention-deficit/hyperactivity disorder. Am J Hum Genet. 1997; 60(6):1276-82. PMC: 1716113. DOI: 10.1086/515485. View